PROGRAM

SCLC

• Strategies for Adding Immunotherapy in First Line SCLC - Shadia Jalal, USA
• What Is The Preferred 2nd Line Treatment of Small Cell Lung Cancer: Immunotherapy, Topotecan, or Lurbinectedin? - Karen Kelly, USA
• Advances in Radiation for SCLC - Alexander Louie, Canada

Mesothelioma

• Immune-checkpoint Inhibitors for Malignant Mesothelioma - Patrick Forde, USA
• Induction Strategies for Malignant Mesothelioma - Bryan Burt - USA
• IMRT Following Ext P/D for Mesothelioma - Andreas Rimner, USA

Lung Cancer Screening

• Lung Cancer Experience in the VA System; Lessons Learned - Anne Melzer, USA
• How to Overcome the Negative Impact of COVID-19 on Deferred Lung Cancer Screening - Nassa Hanner, USA
• Disparities in National Lung Cancer Screening Guidelines: The Multiethnic Cohort Study - Summer Han, USA

Risk Reduction and Tobacco Control

• Criticality of Tobacco Use Assessment in Clinical Trials - Matt Steliga, USA
• Recent FDA Marketing Decision on Heated Tobacco - Maciej Goniewicz, USA

SBRT for Lung Cancer

• Radiomics for Lung SBRT Dose Selection - Mohamed Abazeed, USA
• SBRT vs Lobectomy; The Ongoing VA Randomized Study (VALOR) - David Harpole, USA

2nd Line Therapy

• Should You Continue PD-1/PD-L1 Blockade at the Time of Disease Progression in a Patient That Has Previously Benefited from IO Therapy? - Ticiana Leal, USA
• How Common is Small Cell Transformation in Oncgene-driven Lung Cancer Such as EGFR and ALK? How Can It Be Treated? - Ryan Gentzler
• 2nd Line Therapy Potpouri - Taofeek Owonikoko, USA

Surgery for Early Stage

• Decreasing Opioid Use for Thoracic Surgery - Brendon Stiles, USA
• The Role of Salvage Surgery After SBRT or After Pacific Regimes - Mara Antonoff, USA
• Understanding Commission on Cancer Rules - Daniel Boffa, USA

Patient Survivorship

• Conversations on the Topics of Survivorship and Quality of Life - Laura Petrillo, USA & Sarah Craig, USA

ALL POSTERS WILL BE AVAILABLE TO REGISTERED DELEGATES FOR VIEWING AND DOWNLOADING DURING AND FOR 60 DAYS AFTER THE CONFERENCE. POSTER PRESENTERS CAN BE CONTACTED WITH QUESTIONS VIA THE VIRTUAL PLATFORM MESSAGING FEATURE.

Featured Posters

• Liquid Biopsy to Detect MET Alterations in Patients with Advanced NSCLC: Biomarker Analysis from the VISION Study - Xiuning Le, USA
• KEYNOTE-021 Cohort G Long-term Follow-up: First-line (1L) Pemetrexed and Carboplatin (PC) With or Without Pembrolizumab for Advanced Nonsquamous NSCLC - Mark M. Awad, USA
• Systemic and Intracranial Efficacy of Brigatinib vs Crizotinib: Updated Results from the ALTA-1L Trial - Sanjay Popat, UK
• Improving Quality of Pathology Reports for Resected Non-small Cell Lung Cancer (NSCLC) in the Mid-south US - Matthew Smeltzer, USA
• Circulating Ensembles of Tumor Associated Cells Facilitate Efficient Triaging of Asymptomatic Individuals for Low Dose Computed Tomography - Dadasaheb Akolkar, USA
• Improving Rural Disparity in Lung Cancer Outcomes Starting With An Academic-Community Network Model of LDCT Screening - Charles Shelton, USA
• Delayed ALK Testing Results in the US - Analysis With a Large Real World Oncology Database - Eric Bernicker, USA
• Tolerability, Low-Fat Meal Effect, and Relative Bioavailability (BA) of Oral EGFR Inhibitor TAK-788 in Healthy Volunteers - Steven Zhang, USA
• Economic Burden of Metastatic Non-Small Cell Lung Cancer (mNSCLC) in a Large United States (US) Claims Database - Brian Seal, USA

Posters

Community Practice

• Utilization of Cancer Immunotherapy Prior to Biomarker Test Results Among Patients With Advanced Non-small Cell Lung Cancer in US Community Settings - Aaron Mansfield, USA
• Improving Care for Patients With Stage III/IV NSCLC: Learnings for Multidisciplinary Teams From the ACCC National Quality Survey - Leigh Boehmer, USA
• COVID 19’s Pandemic ‘s Effect on a Community Lung Cancer Screening Program - Goetz Kloecker, USA
• Biomarker Testing Among Users of Online Lung Cancer Resources - Can Online Communities Make a Clinical Impact? - Shayna Yeates, USA
• Relapse Rate and Associated Healthcare Resource Utilization in Stage IIA-IIIB Adjuvant NSCLC Patients Treated in a US Oncology Community Network - Beilei Cai, USA
• Veterans Affairs Insurance Disparities for Metastatic Lung Cancer in the Hawaiian Islands - Stephen Chun, USA

Immunotherapy

• 4-year Survival in Randomised Phase II (POPLAR) and Phase III (OAK) Studies of Atezolizumab vs Docetaxel in 2L+ NSCLC - Julien Mazieres, France

Medical Oncology

• Durvalumab for Patients with Stage III EGFR-Mutated Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy - Jacqueline V. Aredo, USA
• Cost-effectiveness Analysis of Nivolumab Plus Ipilimumab in the First-line Treatment of Metastatic Non-small Cell Lung Cancer in the United States - Malin Berling, USA
• Biomarker Testing Patterns and Treatment Outcomes in Patients With Advanced Non-Small Cell Lung Cancer and MET Exon 14 Skipping Mutations - Beilei Cai, USA
• Management of Selected Adverse Events With Capmatinib: Institutional Experiences From the GEOMETRY Mono-1 Trial - Kelly Goodwon, USA
• Treatment Patterns in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in the Era of Immunotherapy (IO) - David Stenehjem, USA
• Real-World Outcomes of Immunotherapy-based Regimens in First-line Advanced Non-small Cell Lung Cancer - David Stenehjem, USA
• Incidence of Aggressive End of Life Measures in a Retrospective Cohort of High-Risk Patients with Advanced Lung Cancer Receiving Immunotherapy - Ankur Singh, USA
• Phase 2 Basket Trial of Lurbinectedin in Second-line SCLC: Characteristics and Outcomes in Treatment Responders - Vivek Subbiah, USA
• Phase 2 Basket Trial of Lurbinectedin in Small-Cell Lung Cancer (SCLC): Analysis of Efficacy by Baseline Characteristics - Jacob Sands, USA
• Activity of Lurbinectedin in Second-line SCLC Patients Who Are Candidates for Platinum Rechallenge - Vivek Subbiah, USA
• The Relative Survival Impact of Thorough Staging and Appropriate Treatment in Non-Small-Cell Lung Cancer (NSCLC). - Meghan Taylor, USA
• Association of Opioid Use with Survival in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitor Therapy - Joseph Mock, USA
• Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early Stage Non-squamous Non-small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit from Adjuvant Chemotherapy - Gavitt Woodard, USA
• Real-world Effectiveness and Safety of Afatinib Following Immunotherapy (IO) in the Treatment of Metastatic, Squamous Cell/Mixed Histology Carcinoma of the Lung: A Multi-site Retrospective Chart Review Trial in the US - Edward Kim, USA
• Nitric Oxide Lung Cancer Active Vaccination - Hila Confino, USA
• Sociodemographic and Contextual Factors Associated with Biomarker Testing for Patients with Non-Small Cell Lung Cancer in Community Practice - Louise Henderson, USA
• Real-world Characteristics and Outcomes of Advanced NSCLC Patients with Exon 19 or 21 EGFR Mutations - Katherine Winfree, USA
• An Indirect Comparison of Pembrolizumab+Chemo vs Ipilimumab+Nivolumab as First-line Therapies in Patients with PD-L1 TPS≥1% Metastatic NSCLC - Balazs Halmos, USA
• An Indirect Comparison of Pembrolizumab Monotherapy versus Ipilimumab+Nivolumab for first-line Metastatic NSCLC with PD-L1 TPS≥1% - Balazs Halmos, USA
• Pembrolizumab+Chemo versus Atezolizumab+Chemo+/-Bevacizumab for First-line Nonsquamous NSCLC: A Matching-adjusted Indirect Comparison - Balazs Halmos, USA
• Phase 2 GEOMETRY Mono-1 Study: Capmatinib in Patients with METex14-mutated Advanced Non-small Cell Lung Cancer Who Received Prior Immunotherapy - Rebecca S. Heist, USA
• Canakinumab as Adjuvant Therapy in Patients with Completely Resected Non-Small Cell Lung Cancer (NSCLC): CANOPY-A Trial - Alexander I. Spira, USA
• Canakinumab or Pembrolizumab as Monotherapy or in Combination as Neoadjuvant Therapy in Patients with Surgically Resected Non-Small Cell Lung Cancer (NSCLC): CANOPY-N Trial - Jay Lee, USA
• Presentation and Radiographic Characteristics of Leptomeningeal Disease (LMD) in Non-small Cell Lung Cancer (NSCLC) - Cristina Merkhofer, USA
• Second Primary Lung Cancer with NTRK1 Mutation after Initial Primary mEGFR Lung Cancer - Goetz Kloecker, USA
• Three-year follow-up of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, as Second-line (2L) Treatment of Advanced Non-small Cell Lung Cancer (NSCLC) - Luis Paz-Ares, Spain
• A Phase 1b/2, Open-label Study of Bintrafusp Alfa with Chemotherapy in Patients with Stage IV Non-small Cell Lung Cancer - Italia Grenga, USA
• Randomized, Open-label Study of Bintrafusp Alfa vs Pembrolizumab as First-line (1L) Treatment in Patients with PD-L1–expressing Advanced Non-small Cell Lung Cancer (NSCLC) - Everett Vokes, USA
• Trial in Progress: A Phase 1b Study of Sotorasib, a KRAS (G12C) Inhibitor, in Combination with Other Anticancer Therapies in Patients with Advanced Solid Tumors Harboring KRAS p.G12C Mutation (CodeBreaK101) - Gerald Falchook, USA
• Durability of Clinical Benefit and Biomarkers in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Treated with Sotorasib, a KRAS(G12C) Inhibitor - Gregory Durm, USA
• CodeBreaK 200: A Phase 3 Multicenter Study of Sotorasib, a KRAS(G12C) Inhibitor, versus Docetaxel in Patients with Previously Treated Advanced Non-small Cell Lung Cancer (NSCLC) Harboring KRAS p.G12C Mutation - Alexander Spira, USA
• CRESTONE – Clinical Study of Response to Seribantumab in Tumors with NEuregulin-1 (NRG1) Fusions – A Phase 2 Study of the anti-HER3 mAb for Advanced or Metastatic Solid Tumors (NCT04383210) - David Spigel, USA
• Patients with Solid Tumors Harboring NRG1 Gene Fusions: A Real-world Feasibility Study - Sushma Jonna, USA
• Efficacy and Safety of Larotrectinib in Patients with Tropomyosin Receptor Kinase (TRK) Fusion Lung Cancer - Alexander Drilon, USA
• Afatinib in Asian and Non-Asian patients (pts) with EGFR Mutation-positive (EGFRm+) NSCLC Harboring Major Uncommon Mutations - James Chih-Hsin Yang, Taiwan
• Registrational Dataset from the Phase 1/2 ARROW Trial of Pralsetinib (BLU-667) in Patients with Advanced RET Fusion+ Non-small-cell Lung Cancer (NSCLC) - Justin Gainor, USA
• Liposomal Irinotecan in Adults with Small Cell Lung Cancer Who Progressed on Platinum-based Therapy: Subgroup Analyses by Platinum Sensitivity - David R. Spigel, USA
• Trilaciclib Has Myelopreservation Benefits in Patients with Small Cell Lung Cancer Treated with Chemotherapy, Irrespective of Age - Thaddeus Beck, USA
• Using an Exploratory Composite Endpoint to Evaluate the Myelopreservation Benefits of Trilaciclib in Patients with Small Cell Lung Cancer - Janakiraman Subramanian, USA
• Myelopreservation with Trilaciclib Regardless of Risk of Chemotherapy-induced Febrile Neutropenia and/or Anemia or Red Blood Cell Transfusions - Maen Hussein, USA
• Examining the Impact of Tislelizumab Added to Platinum Doublet Chemotherapy on Health-Related Quality of Life in Patients with Non-Squamous NSCLC - Boxiong Tang, China
• Prognostic Factors in Extensive-Stage Small Cell Lung Cancer (SCLC) - Susana Baptista De Almeida, Portugal
• Health-related Quality of Life (HRQoL) in Patients with NSCLC Harboring MET Exon 14 Skipping (METex14) Treated with Tepotinib - Marina Garassino, Italy
• Tepotinib Activity in Brain Metastases (BM): Preclinical Models and Clinical Data from MET Exon 14 (METex14) Skipping NSCLC - Santiago Viteri, Spain
• Tepotinib Exposure-response Analyses of Safety and Efficacy in Patients with Solid Tumors - Wenyuan Xiong, USA
• INSIGHT 2: Tepotinib + Osimertinib in EGFR-mutant NSCLC with Resistance to 1st-line Osimertinib Due to MET Amplification - Niki Karachaliou, Germany
• Low Prognostic Nutrition Index Predicts Poorer Quality of Life in Late Stage Lung Cancer - Lin Gengpeng, China
• Tislelizumab Plus Standard Chemotherapy for Treatment of Advanced Squamous Non-Small Cell Lung Cancer: Patients’ Health Related Quality of Life - Gisoo Barnes, China

Nursing & Allied Health

• Real World Data on Maintenance Therapy Utilization and Overall Survival Among Advanced Non-Small Cell Lung Cancer Patients Treated with Pemetrexed in Combination with Pembrolizumab and Platinum Chemotherapy in the US - Kayonda Bayo, USA

Oligometastatic

• Real-world Clinical Outcomes in Patients with Advanced Non-small Cell Lung Cancer (aNSCLC) in the US - Eric Nadler, USA

Pathology

• Diagnostic and Economic Value of Next-generation Sequencing (NGS) in Genotyping Non-small Cell Lung Cancer Tumors (NSCLC): A Literature Review - Ying Zheng, USA
• Diagnostic and Economic Value of Liquid vs. Solid Tissue Biopsy Procedures for the Detection of Targetable Mutations in Non-small Cell Lung Cancer (NSCLC) Tumors: A Literature Review - Ying Zheng, USA
• Mutational Landscape and Prognosis Prediction for Immune Checkpoint Blockades of DNA Damage Response Pathways in Non-Small Cell Lung Cancer - Jing Zhao, USA

Prevention, Smoking Cessation, Screening and Early Detection

• Evaluation of Circulating Tumor Cells for Non-Invasively Discerning Lung Primary from Metastasis - Dadasaheb Akolkar, India
• Smoking Cessation after Lung Cancer Diagnosis and Risk of Second Primary Lung Cancer: The Multiethnic Cohort Study - Eunji Choi, USA
• A Novel 27-gene Signature Associated with Better Outcomes for NSCLC Patients Treated with IO Therapies with PD-L1 Expression >50%. - Robert Seitz, USA
• A Novel Immunomodulatory Signature Improves Prediction of Response to Immunotherapy Compared to PD-L1 IHC in NSCLC Patients. - Tyler Nielsen, USA
• Racial Differences in Eligibility for Low Dose CT Screening and Burden of Metastatic Disease at Diagnosis of Lung Cancer in the United States - Manoj P Rai, USA
• Integrating Circulating Genetically Abnormal Cells to Early Lung Cancer Screening in Chinese Bus Drivers - Baishen Chen, China
• Predicting Changes in Lung Cancer Risk in the At-Risk Screen Ineligible Population - Andrew CL Lam, Canada
• Simultaneous Multi-Cancer Detection and Tissue of Origin Prediction Via Targeted Bisulfite Sequencing of Plasma Cell-Free DNA - Kathryn Kurtzman, USA

Pulmonary

• Ground Glass Opacity: What’s in a Name? - Eric L. Flenaugh, USA
• AcceleRET Lung: A Phase 3 Study of First-line Pralsetinib in Patients with RET-fusion+ Advanced/Metastatic NSCLC - Benjamin Besse, France
• Effect of Tumor Size Change and Duration of Response on OS With First-Line Pembrolizumab Plus Pemetrexed-platinum For Metastatic Nonsquamous Non‒Small-Cell Lung Cancer - Steven F. Powell, USA

Radiation Oncology

• Prospective Evaluation of Ipilimumab and Nivolumab in Patients with Non-Small Cell Lung Cancer Brain Metastasis - Aditya Juloori, USA

Targeted Therapy

• Real-world Outcomes in Patients with EGFR/ALK-positive NSCLC Treated with Chemotherapy Following 1 or 2 Lines of TKI Therapy - Parneet Cheema, Canada
• Emergence of NOTCH2-NTRK1 after Osimertinib in a Patient with Lung Adenocarcinoma with Neuroendocrine Differentiation - Lin Gengpeng, China
• Drug-Drug Interaction of Oral EGFR Inhibitor TAK-788 With Itraconazole and Rifampin in Healthy Volunteers - Steven Zhang, USA

Translational Science

• HIF-1a Upregulates Muscarinic Receptor 3 and Promotes Invasion and Metastasis in NSCLC - Lin Gengpeng, China
• Novel Anti–CTLA-4 Antibody Quavonlimab Plus Pembrolizumab as First-line Therapy for NSCLC: Extended Follow-up from a Phase 1 Study - Byoung Chul Cho, China
• Efficacy and Safety Data From a Phase 1/2 Trial of Tislelizumab in Chinese Patients With Non-Small Cell Lung Cancer (NSCLC) - Qing Zhou, China
• Racial Disparity in the Timely Treatment of Non-small Cell Lung Cancer - Paige Neroda, USA
• Timely Treatment and Survival for Localized Lung Cancer - Lu Zhang, USA
• High-Plex Digital Spatial Profiling of Non-small-cell Lung Cancer (NSCLC) - Arutha Kulasinghe, Australia
• Genomic HLA as a Predictive Biomarker for Survival Among Non- small Cell Lung Cancer Patient Treated with Single Agent Immunotherapy. - Afaf Abed, Australia